Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giovannoni, G.
Right arrow Articles by Thompson, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giovannoni, G.
Right arrow Articles by Thompson, E. J.
NEUROLOGY 1997;48:1557-1565
© 1997 American Academy of Neurology

Longitudinal study of soluble adhesion molecules in multiple sclerosis

Correlation with gadolinium enhanced magnetic resonance imaging

G. Giovannoni, FCP, M. Lai, MRCP, J. Thorpe, MRCP, D. Kidd, MRCP, V. Chamoun, MRCP, A. J. Thompson, MD, D. H. Miller, MD, M. Feldmann, FRCPath and E. J. Thompson, DSc

From the Institute of Neurology, Department of Neuroimmunology (Drs. Giovannoni, Chamoun, and Thompson) and the Multiple Sclerosis NMR Research Unit (Drs. Lai, Thorpe, Kidd, Thompson, and Miller), London, UK, and the Kennedy Institute of Rheumatology (Dr. Feldmann), Charing Cross Hospital, London, UK.

Objective To assess whether serial serum levels of soluble forms of intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) are useful as surrogate markers of disease activity in multiple sclerosis (MS).

Background Increased levels of sICAM-1 and sVCAM-1 have been described in cross-sectional, but not longitudinal, studies of patients with MS. Although they appear to correlate with clinical and MRI markers of disease activity, their role as potential surrogate markers remains undefined.

Methods Serial serum levels of sICAM-1 and sVCAM-1 were measured in patients with MS undergoing monthly gadolinium-enhanced MRI studies of the brain (462 gadolinium-enhanced MRI in 57 patients) and in 12 normal control subjects. Ten patients had primary progressive (PP), 22 relapsing remitting (RR), and 25 secondary progressive (SP) disease.

Results Levels of SICAM-1 and sVCAM-1 were increased intermittently in patients with all subtypes of MS. Median levels of sICAM-1 were elevated in patients with MS compared with normal controls (normal controls median [interquartile range] = 176[119–209] compared with PP = 502[194–1768], RR = 419[158–481], and SP = 352[196–469] ng/mL; p = 0.04). After excluding patients with PP MS, patients with high sICAM-1 levels had a greater number of gadolinium-enhancing lesions per study (1.9[0.9–4.31) than patients with normal levels (0.4[0–2.7], p = 0.03), and patients with MRI studies with no gadolinium-enhancing lesions had lower associated sICAM-1 levels (200 ng/mL[85–561]) than patients with only persistent (349 ng/mL[82–615]) or new enhancing lesions (497 ng/mL[108–667], p = 0.03). Patients with RR or SP disease that progressed clinically during the study had a greater number of gadolinium-enhancing lesions per MRI study (3.5 [0.4–5.5]) than did patients in whom disease did not proress (1.2 [0.3–2.7], p = 0.03). The patients with progressive disease tended to have higher sICAM-1 levels (469 ng/mL [196–1019]) than patients in whom disease did not progress (353 ng/mL [171–469], p = 0.07). Although MS patients tended to have higher sVCAM-1 levels than did normal controls, this finding was not significant. No correlation could be found between levels of sVCAM-1 and gadolinium enhancement on MRI.

Conclusions: Patients with MS have elevated levels of sICAM-1, which correlate with gadolinium enhancement on MRI and possibly short-term disease progression. Soluble ICAM-1, and not sVCAM-1, may therefore be suitable as a long-term surrogate marker of disease activity in MS.




This article has been cited by other articles:


Home page
NeurologyHome page
D. Cadavid, L. J. Wolansky, J. Skurnick, J. Lincoln, J. Cheriyan, K. Szczepanowski, S. S. Kamin, A. R. Pachner, J. Halper, and S. D. Cook
Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study
Neurology, June 9, 2009; 72(23): 1976 - 1983.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
M. Ukkonen, X. Wu, B. Reipert, P. Dastidar, and I. Elovaara
Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis
Multiple Sclerosis, July 1, 2007; 13(6): 701 - 707.
[Abstract] [PDF]


Home page
Mult SclerHome page
C A B. Hashemi, Y C. Zang, J A Arbona, J A Bauerle, M L Frazer, H Lee, L Flury, E S Moore, M C Kolar, R Y Washington, et al.
Serum immunologic markers in multiple sclerosis patients on continuous combined therapy with beta-interferon 1a, prednisone and azathioprine
Multiple Sclerosis, September 1, 2006; 12(5): 652 - 658.
[Abstract] [PDF]


Home page
Mult SclerHome page
V Yadav, G Marracci, J Lovera, W Woodward, K Bogardus, W Marquardt, L Shinto, C Morris, and D Bourdette
Lipoic acid in multiple sclerosis: a pilot study
Multiple Sclerosis, April 1, 2005; 11(2): 159 - 165.
[Abstract] [PDF]


Home page
BrainHome page
B. Bielekova and R. Martin
Development of biomarkers in multiple sclerosis
Brain, July 1, 2004; 127(7): 1463 - 1478.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
A. Minagar and J S. Alexander
Blood-brain barrier disruption in multiple sclerosis
Multiple Sclerosis, December 1, 2003; 9(6): 540 - 549.
[Abstract] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
Y Zoukos, T N Thomaides, D Kidd, M L Cuzner, and A Thompson
Expression of {beta}2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study
J. Neurol. Neurosurg. Psychiatry, February 1, 2003; 74(2): 197 - 202.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
D. Buljevac, H. Z. Flach, W. C. J. Hop, D. Hijdra, J. D. Laman, H. F. J. Savelkoul, F. G. A. van der Meche, P. A. van Doorn, and R. Q. Hintzen
Prospective study on the relationship between infections and multiple sclerosis exacerbations
Brain, May 1, 2002; 125(5): 952 - 960.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
G. Giovannoni, A. J. Thompson, D. H. Miller, and E. J. Thompson
Fatigue is not associated with raised inflammatory markers in multiple sclerosis
Neurology, August 28, 2001; 57(4): 676 - 681.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
I Duran, E M Martinez-Caceres, L Brieva, M Tintore, and X Montalban
Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis
Multiple Sclerosis, June 1, 2001; 7(3): 151 - 156.
[Abstract] [PDF]


Home page
Arch NeurolHome page
J. R. Avasarala, S. J. Khoury, and H. L. Weiner
Surrogate Markers in Multiple Sclerosis
Arch Neurol, May 1, 2001; 58(5): 834 - 834.
[Full Text] [PDF]


Home page
Mult SclerHome page
N A Losseff, D H Miller, D Kidd, and A J Thompson
The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results
Multiple Sclerosis, February 1, 2001; 7(1): 23 - 25.
[Abstract] [PDF]


Home page
Arch NeurolHome page
I. Elovaara, M. Ukkonen, M. Leppakynnas, T. Lehtimaki, M. Luomala, J. Peltola, and P. Dastidar
Adhesion Molecules in Multiple Sclerosis: Relation to Subtypes of Disease and Methylprednisolone Therapy
Arch Neurol, April 1, 2000; 57(4): 546 - 551.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
I. Duran, E. M. Martinez-Caceres, J. Rio, N. Barbera, M. E. Marzo, and X. Montalban
Immunological profile of patients with primary progressive multiple sclerosis: Expression of adhesion molecules
Brain, December 1, 1999; 122(12): 2297 - 2307.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
E. Waubant, D. E. Goodkin, L. Gee, P. Bacchetti, R. Sloan, T. Stewart, P.-B. Andersson, G. Stabler, and K. Miller
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
Neurology, October 22, 1999; 53(7): 1397 - 1397.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. Trojano, C. Avolio, G. M. Liuzzi, M. Ruggieri, G. Defazio, M. Liguori, M. P. Santacroce, D. Paolicelli, F. Giuliani, P. Riccio, et al.
Changes of serum sICAM-1 and MMP-9 induced by rIFN{beta}-1b treatment in relapsing-remitting MS
Neurology, October 22, 1999; 53(7): 1402 - 1402.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. J. Khoury, E. J. Orav, C. R. G. Guttmann, R. Kikinis, F. A. Jolesz, and H. L. Weiner
Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis
Neurology, September 1, 1999; 53(4): 758 - 758.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
P. S. Surensen
Biological markers in body fluids for activity and progression in multiple sclerosis
Multiple Sclerosis, August 1, 1999; 5(4): 287 - 290.
[Abstract] [PDF]


Home page
Mult SclerHome page
P. Rieckmann, B. Altenhofen, A. Riegel, B. Kallmann, and K Felgenhauer
Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis
Multiple Sclerosis, June 1, 1998; 4(3): 178 - 182.
[Abstract] [PDF]


Home page
Mult SclerHome page
M Trojano, C Avolio, M Ruggieri, G Defazio, F Giuliani, D Paolicelli, and P Livrea
Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFN{beta}-1b treatment
Multiple Sclerosis, June 1, 1998; 4(3): 183 - 187.
[Abstract] [PDF]


Home page
Mult SclerHome page
P. Stinissen, R. Medaer, and J. Raus
Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis
Multiple Sclerosis, June 1, 1998; 4(3): 203 - 211.
[Abstract] [PDF]


Home page
Mult SclerHome page
J D Laman, E J Thompson, and L Kappos
Body fluid markers to monitor multiple sclerosis: the assays and the challenges
Multiple Sclerosis, June 1, 1998; 4(3): 266 - 269.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by AAN Enterprises, Inc.